Health authorities will need to plan for distribution, prioritization, and integration into immunization schedules. Monitoring and surveillance will be vital to assess impact, especially in the states and regions still reporting malaria cases.
In a landmark move toward malaria elimination, the Indian Council of Medical Research (ICMR) has licensed its newly developed indigenous vaccine, AdFalciVax, to five domestic manufacturers. The rollout of this vaccine could prove critical in India’s ambitious goal of achieving zero indigenous malaria cases by 2027 and full elimination by 2030.
Developed by the ICMR’s Regional Medical Research Centre (RMRC), Bhubaneswar, in collaboration with the National Institute of Malaria Research (NIMR) and the National Institute of Immunology (NII), New Delhi, AdFalciVax is a multi-stage recombinant chimeric vaccine designed to block both infection and transmission of Plasmodium falciparum — the deadliest malaria parasite.
Its dual-antigen strategy uses PfCSP (to block the parasite before it enters the bloodstream) combined with fusion proteins Pfs230–Pfs48/45 to reduce onward transmission to mosquitoes.
The vaccine has shown stability and effectiveness at room temperature for over nine months, an important feature for areas with weak cold-chain infrastructure.
Pre-clinical trials have validated its safety and immunogenicity, indicating promise for future human trials and deployment.
In July, ICMR issued an Expression of Interest (EoI) for qualified manufacturers to undertake Technology Transfer for AdFalciVax. From this, five companies have been granted non-exclusive licenses to produce the vaccine:
- Indian Immunologicals Ltd
- TechInvention Lifecare Pvt Ltd
- Panacea Biotec Ltd
- Biological E Ltd
- Zydus Lifesciences
These firms will manufacture and commercialize AdFalciVax under the licensing agreement.
Strategic and Public Health Significance
India’s malaria burden has declined significantly in recent years. According to the World Malaria Report 2024:
- Malaria cases fell from about 6.4 million in 2017 to about 2 million in 2023.
- Deaths dropped from approximately 11,100 in 2017 to around 3,500 in 2023.
- Over 122 Indian districts reported zero malaria cases in 2023.
These gains prompted India to exit the WHO’s High Burden to High Impact category—a recognition of its progress in malaria control.
Despite these successes, malaria hotspots persist in states such as Odisha, Chhattisgarh, Jharkhand, and in regions in the Northeast, especially among tribal populations and border-areas with limited healthcare infrastructure. Flooding and seasonal rises in vector populations have also led to outbreaks in urban peripheries, including Delhi, Noida, and Ghaziabad.
The licensing of AdFalciVax comes at a crucial time. India’s National Framework for Malaria Elimination (2016–2030) and the updated National Strategic Plan for Malaria (2023–27) set forth the target of zero indigenous malaria cases by 2027, followed by full elimination by 2030. AdFalciVax is expected to become a vital tool in accelerating progress.
Currently, while the vaccine has cleared pre-clinical validation and obtained the necessary licensing for commercial production, human trials and real-world deployment are still awaited. Experts believe that combining AdFalciVax with existing malaria control strategies – including Test, Treat, Track, vector control, and community awareness – will be essential.
While the promise is high, several challenges remain:
- Ensuring manufacturing scale-up and quality control across diverse producers.
- Reaching remote, tribal, and border areas with limited healthcare and infrastructure.
- Maintaining cold chain (where needed), although the vaccine’s room-temperature stability offers some relief.
- Integrating vaccination into existing malaria control programmes without compromising other interventions.
- Securing funding, logistical support, and policy backing for widespread rollout.
One of the World’s Deadliest Diseases
With AdFalciVax licensed to domestic manufacturers, India takes a critical step toward being self-reliant (aligned with Atmanirbhar Bharat) in vaccine development and production. By indigenizing technology, the country reduces dependence on imported solutions and accelerates its capacity to respond swiftly to malaria risks.
Public health experts believe that this vaccine could help prevent outbreaks from becoming large-scale, especially in vulnerable zones. The additional layer of immunity could significantly reduce transmission and infection when used in concert with diagnostics, treatment, and vector control.
Next steps include conducting clinical trials in humans to validate efficacy and safety, and then navigating regulatory approvals.
Manufacturers will begin scaling up production now that they hold the licenses. Alongside, health authorities will need to plan for distribution, prioritization (which regions, populations first), and integration into immunization schedules. Monitoring and surveillance will be vital to assess impact, especially in the states and regions still reporting malaria cases.
If successful, AdFalciVax may help India achieve its 2027 zero-cases target and eliminate malaria by 2030, transforming public health outcomes for millions. The world is watching.
Malaria remains one of the world’s deadliest vector-borne diseases. Plasmodium falciparum causes more severe forms of malaria and is responsible for most malaria-related deaths globally. Vaccines against malaria are challenging to develop, due to the complexity of parasite biology and varying stages of infection. India’s multi-stage strategy aims to block infection and interrupt transmission.
India, today, stands at a hopeful inflection point. The licensing of AdFalciVax is more than just a scientific achievement—it is a strategic advancement in health sovereignty and disease elimination. With determined execution, this vaccine could be the key to a malaria-free India.
